Pharmaceuticals, Biotechnology and Life Sciences
IO Biotech, a clinical-stage biopharmaceutical company has dosed the first patient, in metastatic non-small cell lung cancer (NSCLC), in its…
FDA has placed on clinical hold Ocugen’s phase 2/3 study for COVAXIN.
Design Pharmaceuticals, a company redesigning small molecule drug discovery, has announced the closing of a pre-series A round of $5 million, including an investment of $3 million from Virtus Inspire Venture Partners. The proceeds will be used to further build the company’s discovery platform and operations.
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) and Immedica Pharma AB (“Immedica”)have entered a license and supply agreement for Iomab-B, an Antibody Radiation Conjugate comprised of apamistamab, a CD45 targeting antibody, and the radioisotope iodine-131 that is being developed for targeted conditioning to facilitate bone marrow transplant (BMT) and other cell and gene therapies.
Jackson ImmunoResearch, manufacturer of secondary antibodies and immunoreagents for the life science market, has announces a new range of detection reagents that offer superior imaging quality.
List Biotherapeutics, Inc. (List Bio, President: Jonathan Yongwan Jo), a new venture under the Genome and Company umbrella, has announced plans for a new manufacturing facility in the Fishers Life Science & Innovation Park, Indiana after closing their Series A round investment.
Schreiner MediPharm will showcase its new Smart Blister Wallet, which is extendable from 32 to up to 64 cavities, at this year’s Pharmapack in Paris, on May 18 and 19.
Ribonexus, a biotechnology start-up developing new therapies that can overcome resistance to current targeted therapies in cancer patients has received €2 million ($2.19M) in funds from the French public investment bank Bpifrance.
Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, has entered into an agreement with Takeda to expand an existing collaboration to now include the discovery and development of novel therapeutics for fibrostenotic inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis.
Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, has announced today that the Carragelose-based nasal spray has been out-licensed for the South Korean market.